دورية أكاديمية
Progression of clinical markers in prodromal Parkinson’s disease and dementia with Lewy bodies: a multicentre study
| العنوان: | Progression of clinical markers in prodromal Parkinson’s disease and dementia with Lewy bodies: a multicentre study |
|---|---|
| المؤلفون: | Stephen Joza, Michele T Hu, Ki-Young Jung, Dieter Kunz, Ambra Stefani, Petr Dušek, Michele Terzaghi, Dario Arnaldi, Aleksandar Videnovic, Mya C Schiess, Wiebke Hermann, Jee-Young Lee, Luigi Ferini-Strambi, Simon J G Lewis, Laurène Leclair-Visonneau, Wolfgang H Oertel, Elena Antelmi, Friederike Sixel-Döring, Valérie Cochen De Cock, Claudio Liguori, Jun Liu, Federica Provini, Monica Puligheddu, Alessandra Nicoletti, Claudio L A Bassetti, Jitka Bušková, Yves Dauvilliers, Raffaele Ferri, Jacques Y Montplaisir, Michael Lawton, Han-Joon Kim, Frederik Bes, Birgit Högl, Karel Šonka, Giuseppe Fiamingo, Pietro Mattioli, Maria Lorena Lavadia, Jessika Suescun, Kyung Ah Woo, Sara Marelli, Kaylena Ehgoetz Martens, Annette Janzen, Giuseppe Plazzi, Brit Mollenhauer, Mariana Fernandes, Yuanyuan Li, Pietro Cortelli, Michela Figorilli, Calogero Edoardo Cicero, Carolin Schaefer, Lily Guiraud, Giuseppe Lanza, Jean-François Gagnon, Jun-Sang Sunwoo, Abubaker Ibrahim, Nicola Girtler, Claudia Trenkwalder, Luca Baldelli, Amelie Pelletier, Ronald B Postuma |
| المساهمون: | Joza, Stephen, T Hu, Michele, Jung, Ki-Young, Kunz, Dieter, Stefani, Ambra, Dušek, Petr, Terzaghi, Michele, Arnaldi, Dario, Videnovic, Aleksandar, C Schiess, Mya, Hermann, Wiebke, Lee, Jee-Young, Ferini-Strambi, Luigi, G Lewis, Simon J, Leclair-Visonneau, Laurène, H Oertel, Wolfgang, Antelmi, Elena, Sixel-Döring, Friederike, Cochen De Cock, Valérie, Liguori, Claudio, Liu, Jun, Provini, Federica, Puligheddu, Monica, Nicoletti, Alessandra, A Bassetti, Claudio L, Bušková, Jitka, Dauvilliers, Yve, Ferri, Raffaele, Y Montplaisir, Jacque, Lawton, Michael, Kim, Han-Joon, Bes, Frederik, Högl, Birgit, Šonka, Karel, Fiamingo, Giuseppe, Mattioli, Pietro, Lorena Lavadia, Maria, Suescun, Jessika, Ah Woo, Kyung, Marelli, Sara, Ehgoetz Martens, Kaylena, Janzen, Annette, Plazzi, Giuseppe, Mollenhauer, Brit, Fernandes, Mariana, Li, Yuanyuan, Cortelli, Pietro, Figorilli, Michela, Edoardo Cicero, Calogero, Schaefer, Carolin, Guiraud, Lily, Lanza, Giuseppe, Gagnon, Jean-Françoi, Sunwoo, Jun-Sang, Ibrahim, Abubaker, Girtler, NICOLA GIOVANNI, Trenkwalder, Claudia, Baldelli, Luca, Pelletier, Amelie, B Postuma, Ronald |
| بيانات النشر: | GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND OXFORD UNIV PRESS |
| سنة النشر: | 2023 |
| المجموعة: | Università degli Studi di Genova: CINECA IRIS |
| مصطلحات موضوعية: | Parkinson’s disease, REM sleep behavior disorder, dementia with Lewy bodie, evolution, prodromal stage |
| الوصف: | The neurodegenerative synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are characterized by a typically lengthy prodromal period of progressive subclinical motor and non-motor manifestations. Among these, idiopathic REM sleep behaviour disorder is a powerful early predictor of eventual phenoconversion, and therefore represents a critical opportunity to intervene with neuroprotective therapy. To inform the design of randomized trials, it is essential to study the natural progression of clinical markers during the prodromal stages of disease in order to establish optimal clinical end points.In this study, we combined prospective follow-up data from 28 centres of the International REM Sleep Behavior Disorder Study Group representing 12 countries. Polysomnogram-confirmed REM sleep behaviour disorder subjects were assessed for prodromal Parkinson's disease using the Movement Disorder Society criteria and underwent periodic structured sleep, motor, cognitive, autonomic and olfactory testing. We used linear mixed-effect modelling to estimate annual rates of clinical marker progression stratified by disease subtype, including prodromal Parkinson's disease and prodromal dementia with Lewy bodies. In addition, we calculated sample size requirements to demonstrate slowing of progression under different anticipated treatment effects.Overall, 1160 subjects were followed over an average of 3.3 +/- 2.2 years. Among clinical variables assessed continuously, motor variables tended to progress faster and required the lowest sample sizes, ranging from 151 to 560 per group (at 50% drug efficacy and 2-year follow-up). By contrast, cognitive, olfactory and autonomic variables showed modest progression with higher variability, resulting in high sample sizes. The most efficient design was a time-to-event analysis using combined milestones of motor and cognitive decline, estimating 117 per group at 50% drug efficacy and 2-year trial duration. Finally, while phenoconverters showed overall greater ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36881989; info:eu-repo/semantics/altIdentifier/wos/WOS:000977958600001; firstpage:N/A; lastpage:N/A; journal:BRAIN; https://hdl.handle.net/11567/1129002Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85167753835 |
| DOI: | 10.1093/brain/awad072 |
| الإتاحة: | https://doi.org/10.1093/brain/awad072Test https://hdl.handle.net/11567/1129002Test |
| رقم الانضمام: | edsbas.D6F2D6E2 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/brain/awad072 |
|---|